Top Page
Immutep Ltd
(OTC:IMM)
Immutep Ltd (IMM) vs. iShares MSCI Australia ETF (EWA)
Immutep Ltd Business Overview & Revenue Model
Immutep Ltd Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.04M | 5.04M | 3.84M | 3.51M | 170.37K | 3.86M |
| Gross Profit | -56.37M | -56.37M | -37.70M | 1.44M | -1.89M | 1.79M |
| EBITDA | -62.88M | -62.88M | -44.54M | -42.88M | -31.87M | -20.72M |
| Net Income | -61.43M | -61.43M | -42.72M | -39.90M | -32.21M | -29.90M |
Balance Sheet | ||||||
| Total Assets | 156.98M | 156.98M | 201.58M | 147.45M | 102.17M | 82.03M |
| Cash, Cash Equivalents and Short-Term Investments | 129.69M | 129.69M | 181.88M | 123.42M | 80.00M | 60.13M |
| Total Debt | 1.63M | 1.63M | 1.59M | 1.23M | 1.73M | 2.82M |
| Total Liabilities | 13.35M | 13.35M | 12.06M | 10.98M | 8.09M | 8.76M |
| Stockholders Equity | 143.64M | 143.64M | 189.52M | 136.47M | 94.08M | 73.27M |
Cash Flow | ||||||
| Free Cash Flow | -62.10M | -62.10M | -35.75M | -35.93M | -30.25M | -17.66M |
| Operating Cash Flow | -62.05M | -62.05M | -34.82M | -35.88M | -30.23M | -17.64M |
| Investing Cash Flow | -38.53M | -38.53M | -21.02M | -31.00K | -22.91K | -15.60K |
| Financing Cash Flow | -525.12K | -525.12K | 95.18M | 76.04M | 50.33M | 52.68M |
Immutep Ltd Technical Analysis
Immutep Ltd Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | AU$518.99M | ― | -27.89% | ― | ― | 67.26% | |
52 Neutral | AU$375.80M | ― | -35.86% | ― | ― | -19.21% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | AU$294.19M | -20.59 | -83.97% | ― | 1271.12% | 36.87% | |
41 Neutral | AU$97.88M | ― | -42.68% | ― | ― | 63.46% | |
41 Neutral | $100.90M | ― | -83.09% | ― | ― | 55.94% | |
40 Underperform | AU$106.68M | -13.09 | -47.98% | ― | 700.00% | 26.88% |
Immutep Ltd Corporate Events
Immutep Ltd announced a change in the director’s interest, specifically involving Dr. Russell John Howard. The changes include the acquisition and conversion of performance rights into ordinary shares, as approved by shareholders at recent annual general meetings. This adjustment reflects Dr. Howard’s decision to take a portion of his fees in performance rights, aligning his interests with the company’s long-term growth and shareholder value.
Immutep Ltd announced a change in the director’s interest, with Mr. Pete Meyers acquiring 2,058,631 Performance Rights as remuneration for his services. This acquisition, approved at the Annual General Meeting, reflects the company’s strategy to align director compensation with shareholder interests, potentially impacting its governance and stakeholder relations.
Immutep Limited announced a change in the interest of its director, Lis Boyce, who acquired 707,232 Performance Rights and 166,667 Fully Paid Ordinary Shares. These changes were part of a remuneration package approved at the Annual General Meeting, reflecting the company’s strategy to align director compensation with performance and shareholder interests.
Immutep Limited has announced the issuance of 1,800,968 ordinary fully paid securities, which are set to be quoted on the Australian Securities Exchange (ASX) as of December 5, 2025. This move is part of the company’s strategy to enhance its financial position and support its ongoing research and development efforts in the biotechnology sector, potentially impacting its market presence and offering new opportunities for stakeholders.
Immutep Limited announced the issuance of 4,339,509 performance rights as part of an employee incentive scheme, which are not intended to be quoted on the ASX. This move is likely to enhance employee engagement and align their interests with the company’s growth objectives, potentially strengthening Immutep’s position in the competitive biotechnology market.
Immutep Limited announced new data from its AIPAC-003 Phase II trial, which will be presented at the 2025 San Antonio Breast Cancer Symposium. The trial evaluated the combination of eftilagimod alfa (efti) and paclitaxel in heavily pretreated metastatic breast cancer patients, achieving strong objective response rates and immune activation. The study successfully met the FDA’s Project Optimus requirements, establishing 30 mg as the optimal biological dose for efti, which is crucial for ongoing and future clinical programs. This development is strategically important for Immutep’s oncology pipeline, including its global Phase III trial with MSD’s KEYTRUDA® for non-small cell lung cancer.
Immutep Ltd’s recent presentation at their Annual General Meeting 2025 provided an update on the company’s business activities. The presentation emphasized the company’s ongoing efforts and strategic plans, although it included forward-looking statements subject to various risks and uncertainties. Stakeholders are advised to consider these factors carefully, as actual results may differ from current expectations.
Immutep Limited announced promising results from its EFTISARC-NEO Phase II trial, which were presented at the CTOS 2025 Annual Meeting. The trial demonstrated significant tumor hyalinization/fibrosis in patients with soft tissue sarcoma (STS) using a novel combination of eftilagimod alfa (efti) with radiotherapy and KEYTRUDA. This combination showed a strong immune response, potentially leading to better patient outcomes and survival rates. The findings suggest that efti could be beneficial in treating early-stage cancers, expanding its role in the cancer treatment landscape.
Immutep Limited has received a €2,588,954 (~ A$4,567,769) R&D tax incentive payment from the French Government under the Crédit d’Impôt Recherche scheme. This funding will support the global clinical development of eftilagimod alfa and IMP761, enhancing Immutep’s operations and potentially strengthening its position in the biotechnology industry.
Immutep Limited has announced its 2025 Annual General Meeting (AGM) scheduled for November 27, 2025, in Sydney, with provisions for a live webcast for those unable to attend in person. The AGM will address the company’s financial statements and include a resolution on the adoption of the Remuneration Report, which is advisory and non-binding, reflecting the company’s commitment to transparency and shareholder engagement.
Immutep Limited has released its corporate governance statement for the financial year ending 30 June 2025, which is available on their website. The statement, approved by the board, outlines the company’s adherence to the ASX Corporate Governance Council’s principles and recommendations, highlighting its commitment to transparency and accountability in its operations. This disclosure is crucial for stakeholders as it ensures compliance with governance standards, potentially impacting the company’s reputation and investor confidence.
Immutep Ltd has released its annual report for the year ending June 30, 2025, detailing its financial performance and strategic developments. The report highlights the company’s ongoing commitment to advancing its immunotherapy pipeline, which could significantly impact its market position and offer potential benefits to stakeholders in the biotechnology sector.
Immutep Limited has announced promising results from its INSIGHT-003 trial, presented at the ESMO Congress 2025, showcasing a novel combination of eftilagimod alfa (efti) with KEYTRUDA and chemotherapy. This combination has demonstrated strong objective response rates and disease control rates in first-line non-small cell lung cancer (1L NSCLC) patients across all PD-L1 expression levels, particularly benefiting those with low and no PD-L1 expression. The trial results suggest that efti could significantly alter the treatment landscape for 1L NSCLC, providing a new standard of care and addressing the high unmet need in patients with PD-L1 expression under 50%.
Immutep Limited announced positive results from its EFTISARC-NEO Phase II trial, which evaluated the novel combination of eftilagimod alfa (efti) with radiotherapy and KEYTRUDA® in treating resectable soft tissue sarcoma (STS). The trial met its primary endpoint, achieving a 51.5% tumor hyalinization/fibrosis rate, significantly surpassing the historical 15% rate from standard radiotherapy alone. This outcome suggests potential improvements in overall and recurrence-free survival for STS patients, addressing a critical unmet medical need. The findings, presented at the ESMO Congress 2025, highlight the promising efficacy and safety profile of efti, potentially paving the way for new therapeutic options in STS treatment.
Immutep Limited has successfully completed the FDA’s Project Optimus requirements, confirming 30 mg as the optimal biological dose for its immunotherapy candidate efti, which is significant for its oncology pipeline and future Biological License Applications. This development is strategically important for Immutep’s ongoing and future clinical trials, including the Phase III TACTI-004 trial for non-small cell lung cancer, positioning the company to advance its novel immunotherapy to market and address global cancer patient needs.
Immutep Limited has announced a significant milestone in its TACTI-004 (KEYNOTE-F91) Phase III trial for treating advanced non-small cell lung cancer (NSCLC). The trial, which combines eftilagimod alfa with KEYTRUDA and chemotherapy, has enrolled over 170 patients, surpassing the number needed for futility analysis. With over 100 clinical sites activated across 24 countries, the trial is on track for a futility analysis in early 2026. This development could potentially transform the treatment landscape for NSCLC, a major cancer type with high unmet medical needs, by enhancing response rates and improving efficacy regardless of PD-L1 expression.
Immutep Ltd announced a change in the director’s interest, where Mr. Pete Meyers converted 388,889 performance rights into fully paid ordinary shares. This change reflects the director’s compensation strategy, where he receives part of his fees in performance rights, aligning his interests with those of the shareholders.
Immutep Ltd has announced a change in the interest of its director, Dr. Frederic Triebel, involving the conversion of 900,000 performance rights into fully paid ordinary shares. This adjustment, which was previously approved by shareholders, reflects the company’s ongoing commitment to aligning executive incentives with shareholder interests, potentially impacting its market perception and stakeholder confidence.
Immutep Ltd announced a change in the director’s interest, with Mr. Marc Voigt acquiring 1,200,000 fully paid ordinary shares through the vesting and exercise of performance rights. This change reflects the company’s ongoing commitment to aligning executive interests with shareholder value, potentially impacting investor confidence and market perception positively.
Immutep Ltd has announced the issuance of 4,055,555 fully paid ordinary shares, which will be quoted on the Australian Securities Exchange (ASX) starting October 1, 2025. This move is part of the company’s strategy to enhance its capital structure and potentially strengthen its market position, offering stakeholders an opportunity to invest in its growth and development.
Immutep Limited has announced a research collaboration with the George Washington University Cancer Center to initiate a Phase II trial evaluating eftilagimod alfa (efti) as a neoadjuvant therapy for early-stage HR+/HER2-negative breast cancer. The trial will explore efti’s potential to activate a broad anti-cancer immune response, potentially leading to high pathologic complete response rates and improved disease-free survival. This collaboration allows Immutep to expand its clinical pipeline cost-effectively and further positions efti as a promising immunotherapy in both metastatic and neoadjuvant cancer settings.
Immutep Limited announced that data from its EFTISARC-NEO Phase II trial will be presented at the Connective Tissue Oncology Society (CTOS) 2025 Annual Meeting. This trial is the first to evaluate eftilagimod alpha in a neoadjuvant setting combined with radiotherapy and pembrolizumab for soft tissue sarcoma, an orphan disease with significant unmet medical needs. The trial, conducted in Poland and funded by the Polish government, could have implications for the treatment of soft tissue sarcoma, potentially improving outcomes in a field with poor prognosis.